Skip to main content
SpringerLink
Log in

Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Although osteoporosis in men is already a major public health problem, there is still a dearth of data about the effects of risedronate in male osteoporosis, especially in Japanese with primary osteoporosis. Therefore, the objective of our study was to investigate the effects of risedronate on bone mineral density (BMD), bone turnover, back pain, and fractures in these patients prospectively for two years (at baseline, three months, six months, twelve months, and twenty-four months) both longitudinally and compared with those of alfacalcidol. The subjects enrolled for this study were 66 Japanese male patients with untreated primary osteoporosis (mean age 63.52 ± 8.7 years), who were divided into two groups (44 with risedronate and 22 with alfacalcidol). We measured BMD by dual energy X-ray absorptiometry at three sites—the lumbar spine, femoral neck, and distal radius. Risedronate treatment significantly increased BMD at the lumbar spine and at the femoral neck, reduced bone-specific alkaline phosphatase (BAP) and serum N-terminal telopeptide of type I collagen (NTx), and reduced back pain, both longitudinally and compared with alfacalcidol treatment. We observed a lower rate of incident fracture in risedronate users. However, multiple logistic regression analysis revealed that this trend was not statistically significant, possibly because of the small number of patients enrolled. These potentially beneficial effects of risedronate on bone in male patients with primary osteoporosis suggest the possibility that osteoporosis should be treated with risedronate regardless of gender in order to effectively prevent subsequent osteoporotic fractures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Orimo H, Hashimoto T, Sakata K, Yoshimura N, Suzuki T, Hosoi T (2000) Trends in the incidence of hip fracture in Japan, 1987–1997: the third nationwide survey. J Bone Miner Metab 18:126–131

    Article  PubMed  CAS  Google Scholar 

  2. Fujiwara S, Kasagi F, Masunari N, Naito K, Suzuki G, Fukunaga M (2003) Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 18:1547–1553

    Article  PubMed  Google Scholar 

  3. Iwamoto J, Takeda T, Sato Y (2005) Prevention and treatment of corticosteroid-induced osteoporosis. Yonsei Med J 46:456–463

    Article  PubMed  CAS  Google Scholar 

  4. Majima T, Komatsu Y, Doi K, Takagi C, Shigemoto M, Fukao A, Morimoto T, Corners J, Nakao K (2006) Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves’ disease. J Bone Miner Metab 24:105–113

    Article  PubMed  CAS  Google Scholar 

  5. Ringe JD, Faber H, Farahmand P, Dorst A (2006) Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 26:427–431

    Article  PubMed  CAS  Google Scholar 

  6. Shiraki M, Fukunaga M, Kushida K, Kishimoto H, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H (2003) A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the risedronate late phase II research group). Osteoporos Int 14:225–234

    PubMed  CAS  Google Scholar 

  7. Shiraki M, Fukuchi M, Kiriyama T, Okamoto S, Ueno T, Sakamoto H, Nagai T (2004) Alfacalcidol reduces accelerated bone turnover in elderly women with osteoporosis. J Bone Miner Metab 22:352–359

    Article  PubMed  CAS  Google Scholar 

  8. Orimo H, Shiraki M, Hayashi Y, Hoshino T, Onaya T, Miyazaki S, Kurosawa H, Nakamura T, Ogawa N (1994) Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 54:370–376

    Article  PubMed  CAS  Google Scholar 

  9. Shiraki M, Kushida K, Yamazaki K, Nagai T, Inoue T, Orimo H (1996) Effects of 2 years’ treatment of osteoporosis with 1 alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study. Endocr J 43:211–220

    Article  CAS  Google Scholar 

  10. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T, Morii H, Tomita A, Yamamoto K, Nagata Y, Nakashima M, Orimo H (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate phase III osteoporosis treatment research group. Osteoporos Int 10:183–192

    Article  PubMed  CAS  Google Scholar 

  11. Tanizawa T, Imura K, Ishii Y, Nishida S, Takano Y, Mashiba T, Endo N, Takahashi HE (1999) Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures: a retrospective study. Osteoporos Int 9:163–170

    Article  PubMed  CAS  Google Scholar 

  12. Richy F, Ethgen O, Bruyere O, Reginster JY (2004) Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15:301–310

    Article  PubMed  CAS  Google Scholar 

  13. Fujita T, Orimo H, Inoue T, Kaneda K, Sakurai M, Morita R, Yamamoto K, Sugioka Y, Inoue A, Takaoka K, Yamamoto I, Hoshino Y, Kawaguchi H (2007) Clinical effect of bisphosphonate and vitamin D on osteoporosis: reappraisal of a multicenter double-blind clinical trial comparing etidronate and alfacalcidol. J Bone Miner Metab 25:130–137

    Article  PubMed  CAS  Google Scholar 

  14. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H, Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone, Mineral Research (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337

    Article  PubMed  CAS  Google Scholar 

  15. Fujita T, Fujii Y, Okada SF, Miyauchi A, Takagi Y (2001) Analgesic effect of etidronate on degenerative joint disease. J Bone Miner Metab 19:251–256

    Article  PubMed  CAS  Google Scholar 

  16. Takada J, Iba K, Imoto K, Yamashita T (2007) Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate. J Bone Miner Metab 25:142–146

    Article  PubMed  CAS  Google Scholar 

  17. Mashiba T, Mori S, Burr DB, Komatsubara S, Cao Y, Manabe T, Norimatsu H (2005) The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 23:S36–S42

    Article  Google Scholar 

  18. Nakamura T, World Health Organization (2007) Absolute risk for fracture and WHO guideline. Fracture risk assessments recommended by World Health Organization and Japanese guidelines for prevention and treatment of osteoporosis 2006. Clin Calcium 17:1022–1028

    PubMed  Google Scholar 

  19. Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y, Risedronate Phase III Research Group (2006) Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab 24:405–413

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology and Metabolism, Clinical Research Institute for Endocrine Metabolic Diseases, National Hospital Organization, Kyoto Medical Center, 1-1 Mukaihata-cho, Fushimi-ku, Kyoto, 612-8555, Japan

    Takafumi Majima, Akira Shimatsu & Noriko Satoh

  2. Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Takafumi Majima, Yasato Komatsu & Kazuwa Nakao

  3. Department of General Medicine, Rakuwakai Otowa Hospital, Kyoto, Japan

    Takafumi Majima, Kiyoshi Ninomiya & Tadashi Matsumura

  4. First Department of Nursing, Aino Gakuin College, Osaka, Japan

    Atsushi Fukao

Authors
  1. Takafumi Majima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akira Shimatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasato Komatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Noriko Satoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Atsushi Fukao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kiyoshi Ninomiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tadashi Matsumura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazuwa Nakao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takafumi Majima.

About this article

Cite this article

Majima, T., Shimatsu, A., Komatsu, Y. et al. Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study. J Bone Miner Metab 27, 168–174 (2009). https://doi.org/10.1007/s00774-008-0024-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-008-0024-8

Keywords

Search

Navigation